Aimmune secures licence to Xencor’s XmA 7195 to develop food allergy treatments

This article was originally published here

Under an exclusive worldwide licence, Aimmune will develop and commercialise the XmAb 7195, an investigational humanised monoclonal antibody. Xencor president and CEO Dr Bassil Dahiyat said: “Aimmune’s focus,

The post Aimmune secures licence to Xencor’s XmA 7195 to develop food allergy treatments appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply